TheProfitWatch

ALT - Altimmune, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
3.97 -0.01 (-0.25%) --- --- --- -0.06 (-1.51%) 0.02 (0.38%) 0.0 (0.0%) 0.0 (0.0%)

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: AfterHours

Earnings & Ratios

Basic EPS:
-0.27
Diluted EPS:
-0.27
Basic P/E:
-14.6667
Diluted P/E:
-14.6667
RSI(14) 1m:
100.0
VWAP:
3.96
RVol:
0.6918

Events

Period Kind Movement Occurred At
1m Price increase 1m 4.08 +0.04 (+1.12%) Oct 15 09:55

Related News